GLP-1 Users Flag a New Side Effect

The study, flagged by Allure on 2 October 2026, examined adverse event reports linked to GLP-1 receptor agonists — the class of drugs that includes semaglutide and tirzepatide, widely prescribed for type 2 diabetes and weight management. Onycholysis is not new to medicine; it appears as a side effect of several drug classes, including some antibiotics and chemotherapy agents, and can also follow trauma or fungal infection. What the analysis suggests is that GLP-1 medications may belong on that list.

Pharmacovigilance studies draw on self-reported adverse event databases rather than controlled trials, which limits what they can establish. They can identify a signal — an association that warrants closer scrutiny — but they cannot confirm causation, rule out confounding factors, or estimate how often the effect occurs in the broader population of users. A population of roughly 2,000 is also small relative to the tens of millions now taking these drugs globally.

The finding matters less as alarm than as a gap marker: whether the mechanism is vascular, nutritional, or something else entirely is not yet described in the available reporting, and that question will determine whether the risk is manageable or meaningful.